Gochhait Sailesh, Bukhari Syed Irfan Ahmad, Bairwa Narendra, Vadhera Shivani, Darvishi Katayoon, Raish Mohammad, Gupta Pawan, Husain Syed Akhtar, Bamezai Rameshwar N K
National Centre of Applied Human Genetics, School of Life Sciences, Jawaharlal Nehru University, Aruna Asafali Road, New Delhi-110067, India.
Breast Cancer Res. 2007;9(5):R71. doi: 10.1186/bcr1780.
The absence of mutation or promoter hypermethylation in the BRCA2 gene in the majority of breast cancer cases has indicated alternative ways of its involvement, deregulated expression being one possibility. We show how a polymorphism in the 5' untranslated region (UTR) of BRCA2 can serve as one such factor. Based on the hypothesis that variants of genes involved in the same pathway can influence the risk provided for breast cancer, the status of p53 codon 72 polymorphism was also investigated and a possible interaction between the polymorphisms was examined.
The luciferase reporter assay followed by RNA secondary structure analysis was used for the functional characterization of -26 5' UTR G>A polymorphism in BRCA2. The genotype and the allele frequency for the polymorphisms were determined and relative risk adjusted for age was calculated in a case-control study of 576 individuals (243 patients and 333 controls) from north India.
-26 G>A polymorphism in the 5' UTR of BRCA2 was found to be functional whereby the A allele increased the reporter gene expression by twice that of the G allele in MCF-7 (P = 0.003) and HeLa (P = 0.013) cells. RNA secondary structure analysis by two different programs predicted the A allele to alter the stability of a loop in the vicinity of the translation start site. Its direct implication in breast cancer became evident by a case-control study in which the heterozygous genotype was found to be protective in nature (P heterozygote advantage model = 0.0005, odds ratio [OR] = 0.5, 95% confidence interval [CI] = 0.4 to 0.8), which was further supported by trends observed in a genomic instability study. The p53 codon 72 Arg homozygous genotype was found to be over-represented in patients (P = 0.0005, OR = 2.3, 95% CI = 1.4 to 3.6). The interaction study indicated an increased protection under simultaneous presence of protector genotypes of both the polymorphic loci (P = 0.0001, OR = 0.2, 95% CI = 0.1 to 0.4).
Our study shows that -26 5' UTR polymorphism in BRCA2 can modulate the fine-tuned regulation of the multifunctional gene BRCA2 and renders risk or protection according to the genotype status in the sporadic form of breast cancer, which is further influenced by the germline genetic backgrounds of codon 72 polymorphism of p53.
大多数乳腺癌病例中BRCA2基因不存在突变或启动子高甲基化,这表明其参与的方式有所不同,表达失调是一种可能。我们展示了BRCA2基因5'非翻译区(UTR)的多态性如何能作为这样一个因素。基于参与同一途径的基因变体可影响乳腺癌发病风险的假设,我们还研究了p53密码子72多态性的状态,并检测了这些多态性之间可能的相互作用。
采用荧光素酶报告基因检测法并结合RNA二级结构分析,对BRCA2基因 -26 5' UTR G>A多态性进行功能表征。在一项针对印度北部576名个体(243例患者和333名对照)的病例对照研究中,确定了多态性的基因型和等位基因频率,并计算了经年龄调整的相对风险。
发现BRCA2基因5' UTR的 -26 G>A多态性具有功能,在MCF-7细胞(P = 0.003)和HeLa细胞(P = 0.013)中,A等位基因使报告基因表达增加了G等位基因的两倍。通过两个不同程序进行的RNA二级结构分析预测,A等位基因会改变翻译起始位点附近一个环的稳定性。在一项病例对照研究中,其对乳腺癌的直接影响变得明显,该研究发现杂合基因型具有保护作用(杂合子优势模型P = 0.0005,优势比[OR] = 0.5,95%置信区间[CI] = 0.4至0.8),基因组不稳定性研究中观察到的趋势进一步支持了这一点。发现患者中p53密码子72 Arg纯合基因型的比例过高(P = 0.0005,OR = 2.3,95% CI = 1.4至3.6)。相互作用研究表明,两个多态性位点的保护基因型同时存在时,保护作用增强(P = 0.000_{1},OR = 0.2,95% CI = 0.1至0.4)。
我们的研究表明,BRCA2基因 -26 5' UTR多态性可调节多功能基因BRCA2的精细调控,并根据散发性乳腺癌的基因型状态带来风险或保护作用,并进一步受到p53密码子72多态性的种系遗传背景的影响。